Humanized Tauopathy in HUGO Mouse Models: Indication for Advanced AD Pre-Clinical Studies скачать в хорошем качестве

Humanized Tauopathy in HUGO Mouse Models: Indication for Advanced AD Pre-Clinical Studies

Join Cyagen's Study Director, Morris Cui, PhD, for an in-depth look at our advanced humanized mouse models for Alzheimer's disease (AD) and other neurodegenerative conditions. This webinar focuses on hTAU mouse strains, presenting comprehensive validation data that demonstrate their ability to closely mimic human disease pathology. Discover how our proprietary Humanized Genomic Ortholog (HUGO) technology generates robust and highly relevant preclinical models, accelerating neuroscience research and drug discovery. ✅ In this webinar, you will learn: • How our hTAU mouse strains are designed, characterized, and validated. • The application of hTAU models in crucial areas of AD research, from diagnostics to therapeutic strategies. • The innovative HUGO technology and its clear advantages for creating next-generation humanized mouse models. • Our extensive collection of over 100 HUGO strains available for your neurodevelopmental and neurodegenerative disease research. 🎙️ About the Speaker: Morris Cui, PhD, is the Study Director of the Cell and Gene Therapy Department at Cyagen. He earned his Ph.D. from the University of Munich, focusing on Alzheimer’s and Parkinson’s disease at the Center for Neurodegenerative Diseases. With over five years of neuroscience research experience and two years as a clinical neurologist, Dr. Cui brings both scientific and clinical insight to the study of disease mechanisms and therapeutic evaluation. 🔬 Discover Our Solutions: • Neurological Disease Models: https://www.cyagen.com/preclinical-re... • Neuroscience CRO Services: https://www.cyagen.com/cro-services/n... This webinar is for preclinical research professionals, drug discovery organization personnel, and scientists focused on neurodegenerative diseases and neurological studies. Timestamp: ● 00:00 - Introduction to the Webinar & Speaker, Dr. Morris Tui ● 01:27 - Presentation Start: What is the HUGO™ (Humanized Genomic Autolocus) Mouse Model? ● 04:03 - Deep Dive: The Humanized MAPT (Tau) Model & the Importance of 3R/4R Isoforms ● 07:23 - Behavioral Validation: Tracking Cognitive Impairment in P301L & P301S Mutant Models ● 12:35 - Pathological & Biochemical Validation: Detecting Human-Specific Pathological Tau (AT8) in Brain Tissues ● 15:17 - Summary of Validation: A Robust Model Accurately Mimicking Human Tau-Related Disease Progression ● 15:35 - Clinical Relevance: Why Tau is a Better Biomarker & Therapeutic Target than Aβ in AD ● 21:08 - The Future of AD Research: Introducing Cyagen's HUGO™ PLUS Models (e.g., MAPT+, APP+) ● 23:10 - Q1: How does the model mimic human tau pathology (3R/4R Ratio, NFL & Neuron Loss)? ● 25:45 - Q2: How does this model's disease progression compare to existing tau models (e.g., PS19)? ● Starting Sentence: "how is the disease progression and pathology compared to the existing town models" ● 27:49 - Q3: Do you plan to cross the Tau model with other AD models, like Humanized TFRC for antibody drug research? ● 31:10 - Q4: Can you provide a real-world case study of how Cyagen's CRO services use this model? (ASO Drug Example) ● 33:41 - Q5: What is the early customer feedback on using this model for their research? ● 34:54 - Closing Remarks & Special Promotions from Cyagen #Alzheimers #Neuroscience #PreclinicalResearch #MouseModels #DrugDiscovery #Cyagen #Tauopathy #Biotechnology #Webinar